TMO · Q2 2025 Earnings
CautiousThermo Fisher Scientific
Reported July 23, 2025
30-second summary
Revenue grew 3% to $10.85B with organic growth of just 2%, and adjusted EPS came in at $5.36. Management raised the FY2025 outlook (revenue midpoint $43.9B, adjusted EPS midpoint $22.53, operating margin to 22.5–22.7%) on the back of an improved US-China tariff backdrop plus an incremental $300M of cost actions — not on better underlying demand. The bigger signal is the explicit 2026–2027 framework of 3–6% organic growth before reverting to 7%+, which formally extends the "valley" by another two years.
Headline numbers
EPS
Q2 FY2025
$5.36
Revenue
Q2 FY2025
$10.86B
+3.0% YoY
Gross margin
Q2 FY2025
41.2%
Free cash flow
Q2 FY2025
$1.10B
Operating margin
Q2 FY2025
16.9%
Key financials
Q2 FY2025| Metric | Q2 FY2025 | YoY |
|---|---|---|
| Revenue | $10.86B | +3.0% |
| EPS | $5.36 | — |
| Gross margin | 41.2% | — |
| Operating margin | 16.9% | — |
| Free cash flow | $1.10B | — |
Guidance
Prior quarter data unavailable — comparison not possible.
Segment KPIs
Q2 FY2025| Segment | Q2 FY2025 | YoY |
|---|---|---|
| Life Sciences Solutions | $2.499B | +6.1% |
| Analytical Instruments | $1.728B | -3.0% |
| Specialty Diagnostics | $1.134B | +1.5% |
| Laboratory Products and Biopharma Services | $5.995B | +4.1% |
Other KPIs
Q2 FY2025| Segment | Q2 FY2025 |
|---|---|
| Adjusted Operating Margin | 21.9% |
| Organic Revenue Growth | 2% |
| Life Sciences Solutions Segment Margin | 36.8% |
| Specialty Diagnostics Segment Margin | 27.0% |
Management tone
The dominant shift is from generic "navigating macro" framing to an explicit, quantified valley-then-recovery scenario. Management formally introduced a 3–6% organic growth band for 2026–2027 before reverting to a 7%+ long-term algorithm — language not present in prior posture. Mark Casper: "When I look to the future, once this near-term scenario plays out, we expect to deliver 7% plus organic revenue growth." The 7%+ is preserved as the destination, but the timeline to get there is now two years longer than the prior framing implied. That is confidence deferred, not confidence present.
Cost actions are a louder theme than usual. Management disclosed an incremental $300M of cost reduction layered on top of what was already in the original guide: "We've meaningfully stepped up the action as the year has progressed, adding an additional $300 million of cost reduction since the initial guide." The EPS and margin raise this quarter is funded primarily by this, not by topline. That's a tell — discretionary cost control is doing the work while organic growth sits at 2%.
The tariff narrative softened materially. Management acknowledged: "The US-China tariff situation has improved significantly versus our prior guidance assumptions. We reflected the Q2 benefit of that in our revised guidance." But they explicitly kept the FY tariff impact assumption unchanged for the back half given "fluidity," meaning further relief is upside not baked in. That is a deliberately conservative posture, consistent with management leaning defensive.
The customer-relationship framing — "trusted partner status" — was repeated unusually often, paired with reshoring and the Sanofi CDMO deal. This positions TMO's value as defensive optionality in a disrupted environment rather than as growth leverage, a meaningful subordination of the usual innovation-and-M&A pitch.
Recurring themes management leaned on this quarter:
Risks management surfaced:
Q&A highlights
Michael Riskin · Bank of America
Break down the new 7% plus long-term revenue outlook (LRP) into market growth and share gain components, and explain the conviction behind this target given first-half 2025 uncertainty.
Management assumes 3-6% near-term growth driven by academic/government stabilization and clinical research recovery. Long-term 7% plus reflects 4% underlying market growth plus 2-3 points of share gain, underpinned by fundamental healthcare needs, scientific breakthroughs, and strong pharma/biotech pipelines. Management is focused on near-term execution and delivering operating income growth via existing tools (PPI, business systems, AI).
Dan Arias · Stiefel
How much are macro factors influencing biopharma spending decisions, and what characteristics (pipeline, geography, size) distinguish companies pulling back versus investing more?
Pharma and biotech showing mid-single-digit growth with broad strength across bioproduction, pharma services, and research channels. Despite macro uncertainty, customer tone is positive; companies have plans to navigate environment and confidence in pipelines. Large pharma conversing with governments effectively. Described as a 'lean-in environment' with customers depending on Thermo Fisher to execute.
Rachel Vottenstall · J.P. Morgan
Walk through assumptions for three key end markets (pharma/MSN concerns, academic/government funding, China) under the 3-6% midterm framework and rank which are most likely to be resolved by 2026-2027.
Academic/government expected to shift from headwind to growth as budgets normalize (mid-single-digit decline to flat/low single-digit growth). Pharma/biotech to improve from 2025 baseline driven by clinical research momentum and authorizations. China to flatten from high single-digit declines, though may not improve significantly; tariff and economic headwinds persist. None requires major external change; modest improvement across these areas yields 3-6% range.
Jack Meehan · Nefron Research
How will reshoring (specifically the Sanofi CDMO deal) play out over medium term, and did management observe any customer purchasing pauses in Q2 related to uncertainty about future manufacturing locations?
Heightened interest in expanding U.S. manufacturing capacity driven by large pharma. Reshoring represents a one-time tailwind over next few years as facilities come online, then normalizes. No evidence of customer pausing; bioproduction performing very well. Multiple years needed to bring facilities online means capex ramp is gradual.
Tycho Peterson · Jefferies
Are there any reasons pharma services CRO business won't return to high single-digit growth in 2026, and has the longer-term outlook changed? Also, discuss Sanofi CDMO deal opportunity, current capacity in sterile finish, and Accelerator adoption rates.
Clinical research expected to return to growth (not immediately high single-digit) and build from there, driven by authorizations momentum and biotech's dependence on CRO partners. Long-term: high single-digit growth driven by biotech-focused innovation. Sanofi sterile finish acquisition cost-effective way to acquire trained capacity; adds third U.S. site. Accelerator drug development adoption 'incredibly strong' across industry, evidenced in pharma services growth and customer enthusiasm.
What to watch into next quarter
Whether Q3 organic growth actually delivers the implied ~3% (one point above Q2's 2%); a miss here puts the FY 1–3% range at the low end and tests the credibility of the 2026–2027 3–6% framework.
Whether the incremental $300M cost program is repeatable or one-time — specifically whether Q4 commentary introduces further cost actions, which would signal sustained topline pressure rather than transient.
China trajectory: management is assuming high-single-digit declines flatten, not recover. Any further deterioration breaks the 2026–2027 bridge.
Analytical Instruments segment: -3% YoY this quarter on muted equipment demand. Watch whether this stays negative through Q3 or inflects, as it's the cleanest read on capex sentiment among academic/pharma customers.
Sanofi CDMO deal closure before year-end and any incremental reshoring announcements — these are the tangible signals on whether "trusted partner" framing translates into booked revenue or remains narrative.
Adjusted operating margin progression toward the raised 22.5–22.7% FY range; Q2 was 21.9%, implying a meaningful step-up required in H2.
Sources
- Thermo Fisher Q2 2025 Earnings 8-K Exhibit 99.1 — https://www.sec.gov/Archives/edgar/data/97745/000009774525000093/q22025earnings8kex99_1.htm
- Thermo Fisher Q2 2025 earnings call commentary (Mark Casper, Stephen Williamson, and analyst Q&A)
Get the next brief, free.
We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.
This is not investment advice.